GSK To Present Lotronex Risk Management “Progress Report” At May 5 Cmte.
This article was originally published in The Pink Sheet Daily
The meeting comes nearly two years after FDA’s re-approval of the irritable bowel syndrome product. GSK’s risk management program is similar to Roche’s Accutane SMART program, which recently received a committee recommendation for an overhaul.
You may also be interested in...
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.